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FOR MANY YEARS there has been con-
troversy over the incidence of thyroid
dysfunction in patients with breast cancer.
Several studies have revealed elevated
blood levels of thyroid-stimulating hor-
mone (TSH) in breast-cancer patients
(Mittra & Hayward, 1974; Rose & Davis,
1978) andin arecent report (Aldinger etal.,
1978) 36% of patients were found to have
raised blood TSH levels. Others, however,
have found abnormal TSH concentrations
less frequently (Adami et al., 1978). It has
been suggested that reduced thyroid func-
tion may have a role in the development
and progression of breast cancer, and the
American Thyroid Association has called
for carefully designed and controlled
studies of a possible relation between the
thyroid and cancer ofthe breast in humans
(Gorman et al., 1977). We report here the
results of a large study to assess thyroid
function in patients with benign and
malignant breast disease.
We studied 162 consecutive patients
with breast cancer attending the Breast
Clinic from June 1977 to August 1978.
Median age was 55 years (range 26-82)
and 55 patients were premenopausal.
A second group of 60 patients with benign
breast disease was also studied. Median
age was 40 years (range 17-69) and 45
patients were premenopausal. A third
group of 72 female blood donors and
Accepted 14 November 1979
healthy hospital personnel served as
controls. Median age was 52 years (range
23-64) and 21 were premenopausal.
Histological proof of the diagnosis was
obtained in all patients. Blood was taken
from 147 of the cancer group and from 17
of the benign group before surgical re-
moval of the tumour. In the remaining
patients blood was taken 24 h after sur-
gery. Serum was stored at -20°C before
measurement, by immunoassay, of serum
TSH concentration (mU/l), serum triiodo-
thyronine (T3) concentration (nM) and
serum thyroxine (T4) concentrations (nM)
as previously described (Shalet et al.,
1975). The sensitivity of the TSH assay
was 0 5 mU/l. TSH concentrations greater
than 6 mU/l were defined asbeingelevated.
This level represented 2 standard devia-
tions above the mean in the 72 controls.
Statistical evaluation was by one-factor
analysis of variance followed by compari-
son of all pairs of means at a reduced
significance level (1.7%).
Abnormal thyroid function tests were
found in 4/162 patients with cancer, 5/60
patients with benign breast disease and
6/72 controls. One patient with cancer was
clinically and biochemically thyrotoxic,
but in all the others the abnormality was
ofa raised TSH concentration with normal
T3 and T4 levels. Excluding these patients
and controls, mean serum TSH, T3 and T4
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TABLE.-Mean serum TSH, T3 and T4 con-
centrations + s.d. in patients with benign
and nalignant breast disease and controls,




Malignant(158) 1-87+1-03 1-82+0 43 98-84+19-7
Benign (55) 2-87+1-31 1-71+0 39 105-4+23-4
Controls (66) 1-97+1 1 1-88+0 35 89-9+17-9
concentrations + s.d. for the three groups
are shown in the Table. There was no
difference in mean TSH concentration
between the cancer and control groups, but
the benign group had a significantly higher
mean TSH concentration than the other
two groups (P< 0 001). There was no
difference in mean T3 concentration be-
tween the benign and cancer groups or
between the control and cancer groups,
but T3 in the benign group was signifi-
cantly lower than in the other two groups
together (P=0.012). There was no differ-
ence in mean T4 concentrations between
the benign and cancer groups, but T4 was
significantly lower in the control than in
the other two groups (P < 0.001).
Our study is one ofthe largest reported,
and is of value because the patients with
breast cancer were consecutive and un-
selected. To our knowledge, no other study
has used for comparison a group of
patients with benign breast disease as well
as a control group.
We found no increase in the incidence
of thyroid dysfunction in patients with
breast cancer compared to patients with
benign breast disease orto controls. Clearly
abnormal tests were found in only 2.5%
of the breast-cancer patients, compared
to 8.5% of the control and benign breast
disease subjects. Comparison of the tests
within the normal range gives no indica-
tion whatever ofany trend to abnormality
in cancer patients. A raised TSH con-
centration is a sensitive indicator of
impaired thyroid function (Schimmel &
Utiger, 1977). We conclude that thyroid
dysfunction was not associated with the
development of breast cancer in our
patients.
A study of T3 and T4 concentrations
after surgery has shown acute changes,
and this might explain some of the differ-
ences in hormone concentrations in the
benign group, 70% of whom had recently
been operated on, compared to the cancer
and control groups (Chan et al., 1978). In
thesamestudyTSHconcentrations showed
a transient but insignificant rise after
anaesthesia.
Changes are also seen in many chronic
non-thyroid diseases. Low serum T3
concentrations and occasional minimally
elevated TSH concentrations with slightly
increased TSH responses to thyrotrophin-
releasing hormone are found (Schimmel &
Utiger, 1977). Low T3 concentrations and
high TSH concentrations in patients with
malignant lymphoma have been demon-
strated (Brinckmeyer et al., 1977). The
abnormalities were more prominent in
patients with advanced than with early-
stage disease, and were thought to be
secondary to altered peripheral metabol-
ism of thyroid hormones, not due to a
primary abnormality in the pituitary-
thyroid axis. Some ofthe thyroid-function
abnormalities reported elsewhere in breast
cancer may be explained by the same
mechanisms. Our patients all had operable
breast cancer, and continuing analysis of
thyroid function may reveal changes in
hormone levels in relation to the develop-
ment of metastatic disease.
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